Innovative models of germline genetic evaluation are needed for patients with MDS/AML to address systems-level barriers to care, including the development of inpatient genetic counseling and testing ...

Five people living with myelodysplastic syndromes (MDS) or in survivorship talk about their experiences with this serious and commonly misunderstood group of conditions. Myelodysplastic syndromes (MDS ...

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “It looks like, in the low-risk [myelodysplastic ...

Incidence of Non–AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus–Infected Patients Purpose: To assess the incidence and ...

Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of ...

Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating ...

Please provide your email address to receive an email when new articles are posted on . Olutasidenib monotherapy or combination therapy may help certain patients with myelodysplastic syndrome achieve ...

“We saw really quite remarkable outcomes in a very high-risk MDS population, not only in response rates, but also in blood count improvement, long duration of response and improved overall survival,” ...

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced positive preliminary findings from its ongoing multicenter Phase 1 clinical trial ...